CN118660866A - 治疗用改良型氨溴索 - Google Patents

治疗用改良型氨溴索 Download PDF

Info

Publication number
CN118660866A
CN118660866A CN202280079899.3A CN202280079899A CN118660866A CN 118660866 A CN118660866 A CN 118660866A CN 202280079899 A CN202280079899 A CN 202280079899A CN 118660866 A CN118660866 A CN 118660866A
Authority
CN
China
Prior art keywords
compound
disease
ambroxol
subject
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280079899.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·安德森
S·帕斯特纳克
V·雅克
G·布鲁萨德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qiwei Co
Original Assignee
Qiwei Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qiwei Co filed Critical Qiwei Co
Publication of CN118660866A publication Critical patent/CN118660866A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/44—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton bound to carbon atoms of the same ring or condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/68—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/70—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280079899.3A 2021-10-28 2022-10-27 治疗用改良型氨溴索 Pending CN118660866A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272743P 2021-10-28 2021-10-28
US63/272,743 2021-10-28
PCT/US2022/078779 WO2023076997A1 (en) 2021-10-28 2022-10-27 Modified forms of ambroxol for therapeutic use

Publications (1)

Publication Number Publication Date
CN118660866A true CN118660866A (zh) 2024-09-17

Family

ID=84364209

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280079899.3A Pending CN118660866A (zh) 2021-10-28 2022-10-27 治疗用改良型氨溴索

Country Status (7)

Country Link
US (1) US20250235413A1 (enExample)
EP (1) EP4423041A1 (enExample)
JP (1) JP2024540241A (enExample)
KR (1) KR20240095271A (enExample)
CN (1) CN118660866A (enExample)
CA (1) CA3235692A1 (enExample)
WO (1) WO2023076997A1 (enExample)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5354566A (en) 1993-06-02 1994-10-11 Kraft General Foods, Inc. Preparation of yeast-leavened dough crusts
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
IL160539A0 (en) 2001-09-04 2004-07-25 Boehringer Ingelheim Int Anti-influenzal agents
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
DE10332487A1 (de) 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
CA3055311A1 (en) * 2017-02-07 2018-08-16 Stc.Unm Isotope enhanced ambroxol for long lasting autophagy induction
CN114907221A (zh) * 2021-02-06 2022-08-16 华创合成制药股份有限公司 一种氘代氨溴索衍生物及其制备和用途

Also Published As

Publication number Publication date
WO2023076997A1 (en) 2023-05-04
CA3235692A1 (en) 2023-05-04
JP2024540241A (ja) 2024-10-31
EP4423041A1 (en) 2024-09-04
US20250235413A1 (en) 2025-07-24
KR20240095271A (ko) 2024-06-25

Similar Documents

Publication Publication Date Title
TWI634119B (zh) 葡萄糖神經醯胺合成酶抑制劑
US11278531B2 (en) Combination of ibudilast and riluzole and methods of using same
JP2026001009A (ja) リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
US20250177361A1 (en) Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
US12221428B2 (en) Use of deuterated empathogens as therapeutic agents
JP2022514823A (ja) アセチル-ロイシンの重水素化類似体
CN111556750B (zh) 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途
KR102549061B1 (ko) App 의 정상 가공을 촉진하는 화합물
US20250235413A1 (en) Modified forms of ambroxol for therapeutic use
US20250011277A1 (en) Modified forms of ambroxol for therapeutic use
TWI915305B (zh) 包含二羧酸之醫藥組合物及其治療應用
KR102784482B1 (ko) 신경퇴행성 질환 및/또는 그것의 임상적 상태를 억제 및/또는 치료하기 위한 조성물 및 방법
CN1210262C (zh) 1-(4-羟苯基)-2-(4-羟基-4-苯基哌啶-1-基)-1-丙醇的甲磺酸盐三水合物的制备方法
HK1245081A1 (zh) 用於治疗阿尔茨海默病的方法
CN117659024B (zh) 一种酰胺取代的色胺酮类衍生物及其制备方法和应用
CN114767690B (zh) 头孢噻吩酸在制备抗抑郁药物中的应用
US20150366847A1 (en) Combination of geranylgeranylacetone and ibudilast and methods of using same
CN110305087B (zh) 一种5,6-二甲氧基茚酮化合物及其制备方法和用途
CN121987604A (zh) 厚朴酚硝酮衍生物在制备预防或治疗肌萎缩侧索硬化症药物中的应用
KR20240070564A (ko) 알츠하이머병 예방 또는 치료용 약학적 조성물
WO2016084870A1 (ja) アシルアミノフェニル基を有する化合物及びその用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination